Fig. 7: CBX2 predicts survival of HGSOC patients and sensitivity to Ibrutinib. | Cell Death & Disease

Fig. 7: CBX2 predicts survival of HGSOC patients and sensitivity to Ibrutinib.

From: CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer

Fig. 7: CBX2 predicts survival of HGSOC patients and sensitivity to Ibrutinib.The alternative text for this image may have been generated using AI.

a Representative images of patients with non-condensate, condensate, and negative CBX2 patterns. Red, EpCAM; Green, CBX2; Blue, DAPI. Scale bar, 20 μm. b The Kaplan-Meier plot depicts the overall survival, and (c) progression-free survival of patients with all histologies and those with HGSOC presenting varying CBX2 positivity and patterns, and the corresponding hazard ratios (log-rank test, cox-regression). d Representative images of IHC staining of EpCAM, P53, PAX8, WT, and CBX2 of PDOs and their respective tissues of origin. Scale bar, 40 μm. e Representative images of PDOs derived from 8 patients before and after treatment with DMSO and Ibrutinib for 96 hours. Scale bar, 40 μm. f Viability of PDOs with high and low IHC score of CBX2 treated with DMSO and Ibrutinib for 96 h. PDO, patient-derived organoid (unpaired two-tailed Student’s t test). Data represent mean ± SEM of at least three independent biological replicates. ns not significant, *P < 0.05.

Back to article page